Supplements and Featured Publications
Updates in TROP2-Directed and Other Novel ADCs in Breast Cancer
Volume: 1
Issue: 1
Mapping Advances Made in the Realm of Prostate Cancer
Volume: 1
Issue: 1
IRAK4 Inhibition Makes a Splash in B-Cell Malignancies
Volume: 1
Issue: 1
Considering Clinical Updates in Lung Cancer
Volume: 1
Issue: 1
Clinical Updates in Colorectal Cancer
Volume: 1
Issue: 1
Novel Approaches Under Evaluation in Gastrointestinal Stromal Tumors
Volume: 1
Issue: 1
Research Efforts Are Underway for Follicular Lymphoma
Volume: 1
Issue: 1
Novel Approaches Under Evaluation in Melanoma
Volume: 1
Issue: 1
ASCO 2023 Meeting Reporter: Updates in GU Cancers
Volume: 1
Issue: 1
Updates on Advances Made Across the Breast Cancer Treatment Paradigm
Volume: 1
Issue: 1
ASCO and EHA Meeting Reporter: Making the Most of New Data in Myeloproliferative Neoplasms
Volume: 1
Issue: 1
Mapping Advances Made With ADCs in Lung Cancer
Volume: 1
Issue: 1
Clinical Updates in Primary CNS Lymphoma
Volume: 1
Issue: 1
Research Efforts Are Underway for AL Amyloidosis
Volume: 1
Issue: 1
Novel Therapeutic Approaches to Target PI3K Mutations in HR+/HER2– Breast Cancer
Volume: 1
Issue: 1
My Treatment Approach: Utilizing Test Results to Inform Clinical Decisions in NSCLC
Volume: 1
Issue: 1
Research Underway for MYC-Amplified Relapsed or Refractory Solid Tumors
Volume: 1
Issue: 1
2023 Genitourinary Cancers Symposium Meeting Reporter
Volume: 1
Issue: 1
Focus on Pathways: SERMS in Metastatic Breast Cancer
Research Efforts Underway to Target CEACAM5 in NSCLC
Volume: 1
Issue: 1
Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer
Volume: 1
Issue: 1
Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer comprises articles and videos on experts discussing therapeutic strategies in the pipeline and on the market for their patients with non–small cell lung cancer.
Milestones in Medicine: Updates in BPDCN
Volume: 1
Issue: 1
Novel Approaches to Targeting TSC1/TSC2 Across Malignancies
Volume: 1
Issue: 1
Advancing Applications for Antibody-Drug Conjugates in Breast Cancer
Volume: 1
Issue: 1
Examining Recent Developments in Frontline HCC Treatment
Volume: 1
Issue: 1
On the Horizon in NSCLC: Antibody Drug Conjugates
Rapid Reviews in Oncology®: September 2022
Volume: 1
Issue: 1
Novel Therapeutic Approaches to Target FGFR2 Mutations in Cholangiocarcinoma
Volume: 1
Issue: 1
2022 ESMO Meeting Reporter
Volume: 1
Issue: 1
Milestones in Medicine: Updates in AML
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5